Improving safety and efficacy coupled with drug industry desire for “stronger” patents will drive growth of the biologics sector over the next five years, according to new research.
CardioGenics predicts yield boosting “biologics beads” will change the antibody extraction landscape after signing distribution deal with Merck Chimie.
Producing conjugate vaccines in recombinant E coli is potentially simpler and more cost-effective than alternatives, say researchers, but the method suffers from low yields.
Bioprocess purification chromatography tech wins BAC new deal after Swiss protein maker Octapharma licenses it for commercial-scale manufacture.
Pre-clinical ADME contractor Cyprotex upbeat about 2010 despite drop in profit, citing new US opportunities post-Apredica acquisition.
Elan puts plans to sell EDT delivery division on hold because market is not “conducive to an appropriate valuation.”
Catalent Pharma Solutions is offering Optiform, a GSK developed compound optimisation platform, to researchers for the first time.
Outsourcing-pharma presents a round-up of recent developments in the contract research sector, with news from Quintiles, Bioclinica and Cyprotex.
High tech packaging sales and revenue from acquired delivery businesses drive West Pharmaceutical Services growth in second quarter, but US firm cuts guidance.
Cellexus has expanded its disposable bioreactor offering with a unit designed to give biomanufacturers greater flexibility in their choice of cell lines.
Japanese researchers look set to have another option for biomarker analysis, after Thermo Fisher Scientific unveils plans for Tokyo research laboratory unit.
Reaxa has received a UK Technology Strategy Board (TSB) award to further development of cleaner catalysts for pharmaceutical manufacturing.
Preclinical CRO Lab Research says new contracts are a sign of continuing recovery in market as well as firm’s ability to attract broader clientele base.
Pantec Biosolutions AG has secured a CHF20m ($19m) investment to further development of its needle-free in vitro fertilisation (IVF) therapy.
Emergent BioSolutions says additional biomanufacturing space at its Baltimore, Maryland plant could help reduce expenditure through use of new timesaving manufacturing tech.